Semin Hear 2009; 30(1): 047-055
DOI: 10.1055/s-0028-1111106
© Thieme Medical Publishers

Development of Ebselen, a Glutathione Peroxidase Mimic, for the Prevention and Treatment of Noise-Induced Hearing Loss

Eric Lynch1 , Jonathan Kil1
  • 1Sound Pharmaceuticals, Inc., Seattle, Washington
Further Information

Publication History

Publication Date:
29 April 2009 (online)


The development of therapeutics for the prevention and treatment of sensorineural hearing loss remains an elusive goal for auditory scientists and clinicians worldwide. While much research has focused on the histopathology associated with exposure to intense noise or ototoxins (i.e., loss of hair cells), the biochemical and genetic mechanisms that evoke or mediate hair cell death and dysfunction are still under investigation and debate. Many have observed an early oxidative burst in the cochlea that leads to an increase in lipoperoxidation and the activation of cell death pathways, ultimately resulting in apoptosis. In support of this hypothesis, many have protected the cochlea and preserved auditory function by injecting high doses of antioxidants or inhibitors of cell death activation prior to intense noise or ototoxin exposure. Here we discuss a compound currently in Phase II clinical testing for the prevention and treatment of noise-induced hearing loss. This article will review the historic background and pertinent preclinical and clinical data available for ebselen, a novel drug that mimics the activity of glutathione peroxidase, a catalytic antioxidant enzyme that is essential for the peripheral auditory system.


  • 1 Wendel A, Fausel M, Safayhi H, Tiegs G, Otter R. A novel biologically active seleno-organic compound–II. Activity of PZ 51 in relation to glutathione peroxidase.  Biochem Pharmacol. 1984;  33 3241-3245
  • 2 Müller A, Cadenas E, Graf P, Sies H. A novel biologically active seleno-organic compound–I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (ebselen).  Biochem Pharmacol. 1984;  33 3235-3239
  • 3 Yamaguchi T, Sano K, Takakura K et al.. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group.  Stroke. 1998;  29 12-17
  • 4 Pourbakht A, Yamasoba T. Ebselen attenuates cochlear damage caused by acoustic trauma.  Hear Res. 2003;  181 100-108
  • 5 Lynch E D, Gu R, Pierce C, Kil J. Ebselen-mediated protection from single and repeated noise exposure in rat.  Laryngoscope. 2004;  114 333-337
  • 6 Ohlemiller K K, Wright J S, Dugan L L. Early elevation of cochlear reactive oxygen species following noise exposure.  Audiol Neurootol. 1999;  4 229-236
  • 7 Ohlemiller K K, McFadden S L, Ding D L, Lear P M, Ho Y S. Targeted mutation of the gene for cellular glutathione peroxidase (Gpx1) increases noise-induced hearing loss in mice.  J Assoc Res Otolaryngol. 2000;  1 243-254
  • 8 Yamasoba T, Pourbakht A, Sakamoto T, Suzuki M. Ebselen prevents noise-induced excitotoxicity and temporary threshold shift.  Neurosci Lett. 2005;  380 234-238
  • 9 Kil J, Pierce C, Tran H, Gu R, Lynch E D. Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase.  Hear Res. 2007;  226 44-51

Jonathan KilM.D. 

Sound Pharmaceuticals, Inc., 4010 Stone Way N, Suite 120

Seattle, WA 98103